“With a strong balance sheet, significant physician interest in the enVVe valve, and a clearly defined regulatory pathway, we are well positioned to execute the TAVVE study and advance the Company towards multiple near-term and long-term milestones,” said Robert Berman, Chief Executive Officer of enVVeno Medical (NVNO).
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVNO:
- enVVeno Medical announces FDA awarded IDE approval to proceed with TAVVEB study
- enVVeno Medical Wins FDA IDE for TAVVE Trial
- enVVeno Medical reports FY25 EPS ($33.06) vs. ($44.53) last year
- enVVeno Medical expects cash burn rate of $4M-$5M per quarter in 2026
- AI Models Reiterate High-Risk, Speculative View on enVVeno Medical (NVNO)